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1  | INTRODUC TION
The tolerability of AED regimes is crucial to treatment adherence, 
as non-concordance is a major cause of break-through seizures 
for people on long-term AEDs.1 Now that there is significant “re-
al-world” experience alongside trial data with a newer AED, eslicar-
bazepine acetate, we review the available efficacy and tolerability 
data, particularly in comparison with standard AEDs.
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Abstract
The dibenzazepines particularly carbamazepine are associated with known adverse 
effects (AEs) and drug to drug interactions. Eslicarbazepine acetate (ESL) is structur-
ally distinct from other members of the dibenzazepine family and has the advan-
tage of once daily dosing. Observational and trial data report successful switching 
from older dibenzazepines to ESL. The evidence base for doing so is unclear and 
not standardized. This is a literature review following the PRISMA scoping guidelines 
identifying the evidence of switching dibenzazepines. Transition methods, ratios, tol-
erance to change, adverse effects and retention post-change were evaluated. Study 
quality was assessed using the Oxford Centre for Evidence Based Medicine levels of 
evidence. Seven studies investigated the outcome of transition between carbamaz-
epine and or oxcarbazepine to ESL, with specific data on the transition dose ratio and 
scheduling. The available data suggest that the overnight transition between oxcar-
bazepine and ESL in a 1:1 ratio (most common) is generally well tolerated with high 
retention rates. The transition showed improvement in adverse events associated 
with oxcarbazepine across a variety of domains. Almost 60% transitioned because of 
adverse events experienced no further symptoms at 12 months. There is less data on 
the transition from carbamazepine to ESL. The evidence available suggests an over-
night transition in the ratio of 1:1.3-1.5. The retention rate following transition from 
carbamazepine to ESL was 69% (follow-up of 4 months) with almost half of those 
transitioned because of adverse events experiencing no further symptoms. There is 
Grade C evidence available to help guide clinicians in the transition.
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1.1 | Eslicarbazepine acetate
Eslicarbazepine acetate (ESL) is licensed in the United States and 
Europe as an adjunctive treatment for focal-onset seizures with 
or without progression to bilateral tonic-clonic seizures for people 
with epilepsy aged 6 years and older; it can also be used in mono-
therapy in adults. ESL is structurally distinct from other members 
of the dibenzazepine family (carbamazepine [CBZ] and oxcarbaz-
epine [OXC]). There is evidence to suggest that ESL may be better 
tolerated and more efficacious than older dibenzazepines, and ESL 
may be an effective adjunct in individuals previously treated inef-
fectively with CBZ.2 The dibenzazepines are associated with known 
adverse effects (AEs) including dizziness, nausea, hyponatraemia, 
osteopenia and skin reactions. CBZ specifically has major potential 
for significant drug to drug interactions. CBZ is commonly associated 
with increased serum lipid levels, and there is potential for severe re-
bound seizures with both CBZ and OXC when adherence is low.3,4 A 
key difference between ESL and CBZ is the pharmacokinetic profile 
and metabolism which conveys real clinical utility. Eslicarbazepine 
acetate has high bioavailability reaching peak concentration within 
2-3 hours, with a significantly longer half-life of 20-24 hours (de-
pending on population studied). This allows for once daily dosing 
and may minimize the risk of adverse events associated with CBZ 
and OXC, reduce the risk of drug to drug interactions and increase 
concordance.5
1.2 | Efficacy and safety, and tolerability
A pooled analysis from four phase-3 randomized, double blind, pla-
cebo-controlled trials (N = 1703) demonstrates that ESL was associ-
ated with a significant reduction in standardized seizure frequency 
(P < .0001) at doses of 800 mg (33%) and 1200 mg (38%) when 
compared to placebo (18%). The responder rates (≥50% reduction 
in seizures over 4 weeks) were 34% (800 mg) and 43% (1200 mg) 
compared to 22% in the placebo group.6 A post hoc pooled analysis 
of three randomized, placebo-controlled trials in adults with treat-
ment-resistant focal-onset seizures assessed the safety (N = 1447) 
of adjunctive ESL.7 ESL was generally well tolerated, and treatment-
related adverse events were dose related (lower incidence for those 
initiated at 400 mg). Those adverse events leading to discontinua-
tion were 28 (6.6%) in the placebo arm vs 179 (17.5%) in the ESL 
group. Adverse events overall also appeared to be dose related 
(19/196 at 400 mg, 104/410 at 1200 mg). The overall incidence of 
serious adverse events was less than 10%. The most common events 
leading to discontinuation in the ESL group were dizziness, nausea 
and vomiting.7
1.3 | Monotherapy
In the monotherapy setting, two trials including a total of 332 pa-
tients from multiple centres have described the efficacy of ESL in 
patients who were switched from CBZ and/or other AEDs.8 Patients 
on average achieved a reduction of seizure frequency (calculated 
per 28 days) of 43% with ESL 1600 mg and 36% with ESL 1200 mg. 
The magnitude of reduction was less for patients who were taking 
CBZ at baseline (12% on ESL 1200 mg and 28% on ESL 1600 mg) 
than for those who were not (45% on ESL 1200 mg and 50% on ESL 
1600 mg).8
The largest cohort of patients from real-world experience was 
analysed in the Euro-ESLI study, which assessed the effective-
ness, safety and tolerability of ESL when used in everyday clinical 
practice in Europe.9 Data were obtained retrospectively from a 
number of heterogeneous clinical studies and pooled for analysis. 
Data from 2058 patients were included. A total of 2058 patients 
were assessed for safety, and 1975 patients were assessed for ef-
fectiveness. AEs were reported for 34.0% of patients and led to 
discontinuation in 13.6% of patients. At 12 months, the overall re-
sponder rate (≥50% reduction in seizures) was 76% with a seizure 
freedom rate of 41%. Of the 2058 patients included in the total 
analysis, 233 (11%) were transitioned from CBZ to ESL. One hun-
dred and sixty-three of the 233 patients (70%) were responders 
at 12 months, and the seizure freedom rate was 31%. Among pa-
tients who transitioned from CBZ to ESL due to lack of efficacy, 11 
patients out of 105 demonstrated unchanged or worsened seizure 
frequency at 12 months.9
The safety profile has also been reported in a small real-world 
study, which analysed 108 patients in Spain.10 Among 108 pa-
tients, 52% switched from older dibenzazepines (either CBZ or 
OXC). Laboratory values concerning lipid metabolism profile, liver 
function tests (LFTs) and sodium were assessed before and after 
switching treatment. Patients switching from prior dibenzazepines 
showed significant reductions in mean low-density lipoproteins 
(LDL) and triglycerides (P < .05). No differences were detected 
in other mean laboratory values, including sodium levels.10 The 
Euro-ESLI data have undergone several further subgroup analy-
ses, including specific investigation into monotherapy. The data 
are concordant with observational evidence such as the prospec-
tive multicentre study in 17 hospitals in Spain which demonstrated 
a responder rate of 83% (N = 49) at 12 months, and adverse event 
rate of 15% (N = 18).11
It is clear that clinicians are switching from CBZ and OXC to 
ESL but best practice for how to make the change is unclear. We 
review the evidence base for switching, specifically considering 
the mode of switching between AEDs (slow transition or imme-
diate), dose ratio, and the impact upon safety, tolerability and 
efficacy.
2  | METHODS
2.1 | Inclusion/Exclusion criteria
The PRISMA scoping review guidelines were followed (Appendix 
A1). This review included randomized controlled trials and 
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uncontrolled prospective and retrospective cohort studies re-
porting outcomes from a “switch” between CBZ and/or OXC and 
ESL, including information on how this transition was achieved. 
Studies were included if they reported: data observing dose titra-
tion method (ratio) of switching to ESL from CBZ and/or OXC and 
compared either efficacy and/or safety/tolerability before and 
after switching. Outcome measures included adverse events, re-
tention rate, responder rate (≥50% reduction in seizures), change 
in seizure frequency and quality of life according to validated gen-
eral scales such as the 36-Item Short Form Health Survey (SF-36), 
EuroQol 5-Dimensions (EQ-5D) or epilepsy-specific scales such as 
the Quality Of Life In Epilepsy-31 (QOLIE-31). Exclusion criteria 
included: no data on transition between dibenzazepines’ and lack 
of meaningful comparable outcome data.
2.2 | Search strategy
A search was conducted on Medline (1946 to 31 July 31 2019), Embase, 
PsychINFO, and the Cochrane Library of Systematic Reviews using 
search terms and subject headings: eslicarbazepine and carbamaze-
pine or oxcarbazepine with no language or date restrictions (Appendix 
S1). We reviewed the reference lists of retrieved trials to check for ad-
ditional reports of relevant studies and included grey literature.
2.3 | Data collection and analyses
We reviewed the outcome data from each study in detail with a view 
to pooling results to help consolidate the evidence available. There is 
dichotomous data available regarding responder rates, retention rates, 
and there are similar validated tools used to measure adverse events 
and quality of life outcomes across investigations. However, the het-
erogeneity of methodologies suggests that a descriptive review would 
be more appropriate. The barriers to pooling data include significant 
differences in inclusion and exclusion criteria, follow-up period, ratio of 
transition between dibenzazepines, retrospective vs prospective data 
collection and in some cases a lack of data available.
3  | RESULTS
We identified 841 records that fulfilled the search criteria. Animal 
studies (30) and duplicate studies (209) were removed leaving 602 
records. These records were screened with 564 excluded based on 
title and abstract. Full-text screening of the remaining 38 records 
led to 31 being excluded due to no data on transition ratio between 
dibenzazepines (11) review articles (5), ESL monotherapy (4), no ESL 
data (3), erratum responses (2), duplicate data (3), pharmacokinetic 
study (1), only data on children (1) and only lipid data (1). Seven stud-
ies were included within this review (Table 1).
All seven studies include data on the ratio and schedule of tran-
sition between dibenzazepines. Data are included on a total of 203 
individuals; however, two of the studies were subgroup analyses of 
larger populations. Of the seven studies, five were prospective, ob-
servational, uncontrolled, single-centre designs. A subgroup analysis 
from a larger retrospective, multicentre, uncontrolled observational 
investigation was also included. Because of limited data, we also in-
cluded conference abstracts (2) that met the inclusion criteria. All 
seven studies included some data on tolerability and adverse events. 
Four of the seven investigations included some data on efficacy. 
Seven studies reported on transition from OXC to ESL and two stud-
ies reported on the transition from CBZ to ESL. Due to heterogene-
ity in study design and dose schedules, it was not possible to pool 
outcome data. The results are therefore presented as a narrative 
review.
3.1 | Transition dose ratio between AEDs
No data on comparisons between switching regimes or dose ratio were 
identified for transitions between OXC and ESL, or CBZ and ESL.
3.1.1 | OXC to ESL
The most common transition from OXC to ESL was an overnight 
switch in a ratio of 1:1 (5 studies, N = 145). One prospective obser-
vational study (N = 19) initially transitioned with an overnight switch 
ratio of 1:0.7 (OXC:ESL) and then increased ESL dose to a ratio of 
1:1 after 3-day treatment.12 Another prospective study included ob-
served an overnight switch in a varying dose ratio between 1:1.1 and 
1:1.9 (OXC:ESL).13
3.1.2 | CBZ to ESL
The review identified less data on the ratio of switch between 
CBZ and ESL (2 studies, N = 58). A subgroup analysis (N = 13) of 
a prospective observational study transitioned overnight in a ratio 
of 1:1.3 (CBZ:ESL).14 A retrospective, multicentre study subgroup 
analysis (N = 45) observed an overnight transition in a ratio of 1:1.5 
(CBZ:ESL).15
3.2 | Efficacy
3.2.1 | OXC to ESL
Three studies reported on efficacy outcomes in 84 patients switch-
ing from OXC to ESL. An open-label prospective observational study 
in Spain included 12 individuals as part of a larger cohort of 61 pa-
tients with treatment-resistant epilepsy, on a variety of concomitant 
AEDs. The transition from OXC to ESL was conducted overnight 
in a dose ratio of approximately 1:1 (eg those prescribed OXC at 
400 mg were switched directly to ESL 400 mg). Eleven of those 
6  |     WATKINS eT Al.
included were followed up for at least 3 months (mean follow-up 
time 5.25 ± 2.3 months). One individual achieved seizure freedom, 
an additional 4 (36%) achieved ≥50 per cent reduction in seizure 
frequency, one experienced no change, and one experienced an in-
crease in seizure frequency.14
A retrospective multicentre study (n = 327) in Spain (ESLIBASE) 
investigating individuals with focal seizures across 12 hospital sites 
over a 2-year period included 48 individuals who switched from OXC 
to ESL. The transition from OXC to ESL was conducted overnight in a 
dose ratio of 1:1. investigators observed a 12-month responder rate 
(≥50 % reduction in seizure frequency) of 46%, a seizure freedom 
rate of 31% (baseline before inclusion 16%) and epilepsy worsened 
in 17%.15 A single-centre study in Finland (N = 23) followed individ-
uals transitioned from OXC to ESL overnight in a dose ratio of 1:1. 
no significant change in seizure frequency was observed over a 1- to 
3-month follow-up period.16
3.2.2 | CBZ TO ESL
The two Spanish studies discussed above also investigated the ef-
ficacy of switching from CBZ to ESL in a total of 58 participants. 
The larger retrospective investigation included 45 participants that 
transitioned from CBZ to ESL. This switch was made overnight in 
a dose ratio of 1:1.5 (CBZ:ESL). Investigators observed a 12-month 
responder rate of 39%, seizure freedom in 11% (baseline 13%) and 
epilepsy worsened in 17%.15
Thirteen people with treatment-resistant epilepsy were tran-
sitioned from CBZ to ESL in a post-authorization observational 
study. The switch was made overnight in a dose ratio of 1:1.3 
(CBZ:ESL). However, only eight individuals who switched were 
monitored for at least 3 months. In these cases, one patient re-
mained seizure free, one responded, three demonstrated no sig-
nificant change, and a further three experienced an undefined 
increase in seizure frequency.14
3.3 | Adverse events
All seven studies involving a total of 203 participants included 
within this review included some outcome measure related to ad-
verse events. In the prospective observational study conducted in 
Spain, four of the 12 patients who switched from OXC to ESL (1:1 
dose ratio) experienced the same adverse event: drowsiness. Two 
individuals reported that adverse events associated with OXC (diz-
ziness and drowsiness) improved on switching to ESL. The retention 
rate for the OXC to ESL group was 100% (mean follow-up time was 
approximately 5 months). In the CBZ to ESL (1:1.5 dose ratio) group, 
8 out of 13 patients’ experienced adverse events (dizziness and nau-
sea, 4; anxiety, 2; insomnia, 1; constipation, 1; pruritic rash, 1). The 
retention rate (mean follow-up approximately 4 months) for the CBZ 
to ESL group was 69%.14
In the ESLIBASE subgroup analysis, 26 individuals were switched 
to ESL from OXC (1:1 dose ratio) because of side effects. Of those 
switched, 15 out of 26 no longer had any adverse effects, while 
for 11 out of 26 the adverse effect continued. Seventeen individu-
als were switched from CBZ to ESL (1:1.5) because of side effects. 
Following transition 8 out of 17 no longer experienced adverse ef-
fects, 9 (53%) continued to experience adverse events.15
In a single centre prospective study in the inpatient setting, 23 
patients were specifically identified for transition from OXC to ESL 
(1:1 dose ratio) because of adverse events related to OXC. Those 
included were most commonly on two other AEDs. The adverse 
events reported prior to the switch were most commonly fatigue (al-
most 50%), followed by vertigo and dizziness. Following the switch 
to ESL, 15 out of 23 patients experienced a significant reduction in 
adverse events. Following transition, almost all (93%) of the adverse 
events that presented in the morning resolved. The incidence of ad-
verse events associated with ESL declined during follow-up (39% at 
1 month, 13% at 3 months). There was a 100% retention rate during 
the 3-month follow-up period.16
A small prospective observational study (N = 19) has demon-
strated that a switch to ESL (dose ratio 1:0.7, increased to 1:1 
after 3 days) in individuals with focal epilepsy on high dose OXC 
does not affect serum sodium levels.12 An overnight switch from 
OXC to ESL (dose ratio 1:1) was examined prospectively over a 
5-day period with standardized testing before and after transition 
(n = 12). No significant differences were identified on measures 
of adverse events, quality of life or alertness. Serum sodium level 
TA B L E  2   The EPICON25 recommendations for transition from 
CBZ or OXC to ESL
A switch from CBZ to ESL over a period of 1-3 wk with a CBZ:ESL 
dose ratio of 1:1.3.
Patient characteristics
Low concordance with medication.
Patients working shift patterns/unusual hours.
Patients on multiple medications.
Cognitive problems.
Severe osteoporosis or osteopenia.
Dyslipidaemia.
Liver disease other than acute liver failure.
Men with erectile dysfunction caused by CBZ.
A switch from OXC to ESL is well tolerated even with an overnight  
switch in a 1:1 ratio.
Patient characteristics
Low concordance with medication.
Patients working shift patterns/unusual hours.
Patients on multiple medications.
Cognitive problems.
*Transition to ESL is not recommended for individuals with a rash 
associated with CBZ or OXC treatment. 
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decreased in 9 out of 12 participants but never to a clinically sig-
nificant level.17
A small (N = 10) prospective observational investigation exam-
ined the tolerability of overnight switch (dose ratio variable 1:1.1 
−1.9) in adults with uncontrolled focal seizures. The mean dose after 
switching was 800 mg. investigators applied the adverse event pro-
file (AEP), a standardized test for alertness and the quality of life in 
epilepsy inventory-10 (QOLIE-10). At day-5 following the switch to 
ESL, there was a significant reduction in AEP scores (P = .005). there 
were no statistically significant differences on the other outcome 
measures.13 A retrospective, single centre study (n = 21) in patients 
with treatment-resistant focal seizures (81% temporal lobe epilepsy) 
also used similar outcome measures. An overnight switch was per-
formed between OXC and ESL (dose ratio 1:1) with AEP score and 
QOLIE-10 scores taken before the switch and 5 days post-transi-
tion. there were statistically significant improvements in AEP score 
(P < .001), QOLIE-10 (P = .001) and alertness (p < .05) in the short 
term, with no comment on clinical significance. The AEP score im-
proved for all patients after switch. the QOLIE-10 scores remained 
the same or worsened for 4 out of 21 patients. The alertness score 
(reaction time) remained unchanged or worsened in 5 out of 21. 
There was no impact upon serum sodium level.18
4  | DISCUSSION
In contrast to CBZ and OXC, it has been shown that Esli appears to 
lack any clinically meaningful interaction with other enzyme induc-
ing AEDs.5 This is of real clinical benefit in the management of treat-
ment-resistant epilepsy. CBZ in particular is known to be associated 
with a vast range of drug to drug interactions, some of which may 
affect the pharmacokinetics of CBZ leading to safety concerns due 
to the narrow therapeutic window. In addition, CBZ’s potent enzyme 
inducing effects in the liver influence the metabolism of a wide range 
of drugs for many different conditions. The pharmacokinetic profile 
of Esli may offer particular benefit to people with multiple comor-
bidities, concomitant medications and the elderly.19
This review identified seven studies that investigated the out-
come of transition between CBZ and or OXC and ESL, with specific 
data on the transition dose ratio and scheduling. The data available 
suggest that the overnight transition between OXC and ESL in a 1:1 
ratio (most commonly) is generally well tolerated with retention rates 
between 70% and 100% (5 days to 5 months). The transition to ESL 
has also demonstrated improvement in adverse events associated 
with OXC across a variety of domains. Almost 60% of individuals’ 
who transitioned from OXC to ESL because of adverse events ex-
perienced no further symptoms at 12 months.15 Any adverse events 
associated with the introduction of ESL itself reduced with time. The 
data available suggests no negative impact upon seizure control and 
a responder rate (≥50% reduction in seizures) of almost half at 12-
month follow-up.15
All of the papers included in this review expect one investigated 
the transition from immediate release OXC to ESL. There is evidence 
to demonstrate that OXC extended-release formulation is associ-
ated with better tolerability.20 However, the OXC extended-release 
formation is not available in all regions and so this review is clinically 
relevant.
There is less data available for comparison on the transition from 
CBZ to ESL. The transition ratio varied between 1:1.3 and 1:1.5. 
Retention rate following transition has been reported as 69% with 
a mean follow-up period of four months,14 with almost half of those 
transitioned from CBZ to ESL because of adverse events experienc-
ing no further symptoms.15 The limited data from one investigation 
on efficacy report a responder rate of almost 40% at 12-month 
follow-up.15
Hyponatraemia is a clinically important consideration when pre-
scribing dibenzazepines. This review only identifies limited data that 
may help inform prescribing choices. In a population of individuals 
(N = 19) with pre-existing low sodium levels prescribed OXC, there 
was no significant impact upon serum sodium levels on long-term 
follow-up (1, 6, 12 and 18 months), even at higher dosege.12 When an 
immediate switch was conducted from OXC extended-release for-
mulation to ESL decreased serum sodium was observed at 5 days in 
nine of 12 participants. However, no one experienced hyponatrae-
mia of a clinically concerning level requiring intervention or medica-
tion change.17
Non-concordance with AEDs is a major contributing factor to 
treatment failure in epilepsy.21 This can lead to significant risks to pa-
tient safety including injury, hospitalization and sudden unexpected 
death in epilepsy (SUDEP).22 When patients experience side effects 
from prescribed medications. adherence is poor.23 Unfortunately, 
the studies included in this review do not identify any specific mark-
ers of AED concordance such as serum AED levels. We can therefore 
only speculate based on surrogate markers such as seizure control 
and retention rates.
5  | LIMITATIONS
The investigations identified are heterogeneous in terms of sample 
population, methodology and outcome measures. Therefore, it has 
not been possible to pool any available data for further analysis. 
The studies are observational, with no comparative data such as 
different dosing ratios or schedules for switching between AEDs. 
The sample sizes in each study are small, and where samples are 
larger these consist of subgroups derived from wider investiga-
tions. Inclusion and exclusion criteria vary between investigations, 
although the broad base of population characteristics is generally 
similar. These characteristics include diagnosis of epilepsy, with 
focal seizures, concomitant AED prescription and treatment re-
sistance as may be expected given ESL licensing and indication. 
There is significant risk of inherent bias in all studies included due 
to the observational design, patient selection, sample sizes, short 
follow-up periods, and lack of comparative groups for a randomi-
zation and blinding process. One positive regarding these obser-
vational studies is that outcomes may be more pragmatic. The 
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nature of some of the studies included (conference proceedings) 
does not allow for formal assessment of bias due to lack of data.
Based on the findings in this review, there is Grade C evidence24 
available to help guide clinicians on when and how to transition 
patients from CBZ or OXC to ESL. A Delphi Consensus paper has 
described recommendations (Table 2) on how to switch from CBZ 
and OXC to ESL.25 This recommendation is based upon ESL clinical 
data and clinical practice experience of 54 epilepsy experts.
This review does not provide significant new information to 
influence how transition from OXC or CBZ to ESL should be con-
ducted. The evidence available is based on a transition from both 
OXC and CBZ overnight with some positive outcomes in the lim-
ited data set. There is a lack of data comparing dosing regimens and 
titration periods. As discussed, the pharmacokinetic profile of ESL 
may be beneficial for certain populations with particular charac-
teristics. However, to date there is a lack of robust evidence exam-
ining whether this benefit is observed in a clinically relevant way.
6  | CONCLUSION
There is low level Grade C evidence24 available based on data from 
heterogeneous observational cohort studies to support the method 
of transition between older dibenzazepines and ESL. The data that 
are available from pragmatic observational investigations demon-
strate that transition from CBZ and or OXC to ESL may be effective, 
and it is in general well tolerated. The pharmacokinetic profile of ESL 
suggests that it may be beneficial for individuals experiencing side 
effects from other dibenzazepines, lack of efficacy, lowered adher-
ence and/ or risk of drug to drug interactions. However, at present 
data to support the switch in particular populations is not available. 
There is a clear need for a rigorous scientific investigation to be per-
formed in large representative real-world cohorts across multiple 
sites, with comparative groups for transition ratio, schedule, and 
those who do not switch between AEDs.
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APPENDIX A1
SE ARCH S TR ATEGY
Medline, PsychINFO and the Cochrane Library of Systematic Reviews using search term and subject headings for ‘Eslicarbazapine’ and 
‘Carbamazapine’ or ‘Oxcarbazapine’, with no language or date restrictions, including grey literature.
